22 completed, 10 active not recruiting, 10 terminated, 4 withdrawn. 20 Phase 1, 20 Phase 2, 4 Not applicable, 3 Phase 3, 2 Early Phase 1.
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nipple Aspirate Fluid in Detecting Breast Cancer Aspiration of Breast, Biospecimen Collection - Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 2 | 2020-12-10 | 2025-02-25 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Pembrolizumab, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Withdrawn | University of Washington | 2019-04-01 | 2019-04-26 | |
| Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502 Screening Mammography, Biospecimen Collection - Breast Carcinoma, Estrogen Receptor Negative | Terminated | Alliance for Clinical Trials in Oncology | 18 | 2019-02-26 | 2025-01-16 | |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Biopsy, Chemokine Modulation Therapy, Celecoxib - Triple -Negative Breast Cancer, Estrogen Receptor Negative | Early Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2019-01-09 | 2023-07-18 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Durvalumab, Olaparib - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative | Phase 1 | Completed | OHSU Knight Cancer Institute | 3 | 2018-05-03 | 2020-11-20 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| IACS-010759 in Advanced Cancers Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2017-11-13 | 2020-11-24 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | Northwestern University | 12 | 2017-09-14 | 2026-06-17 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer Mirvetuximab Soravtansine - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2017-06-05 | 2020-12-02 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Completed | City of Hope Medical Center | 18 | 2017-06-01 | 2024-02-20 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis - BARD1 Gene Mutation, BRCA1 Gene Mutation | Not applicable | Suspended | M.D. Anderson Cancer Center | 5200 | 2017-04-18 | 2026-08-26 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Estrogen Receptor Negative, HER2 Positive Breast Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 120 | 2017-01-20 | 2026-09-25 |
| DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography - Estrogen Receptor Negative, HER2/Neu Negative | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 96 | 2016-11-07 | 2026-10-07 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Breast Lump | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2016-10-06 | 2026-10-06 |
Showing 20 of 49. Sign in to see all of them.
Triple Negative Breast Neoplasms (44) · Breast Neoplasms (35) · Ovarian Neoplasms (6) · Breast Neoplasms, Male (4) · Carcinoma, Non-Small-Cell Lung (4) · Fallopian Tube Neoplasms (4) · Inflammatory Breast Neoplasms (4) · Pancreatic Neoplasms (4) · Carcinoma, Renal Cell (3) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Carcinoma In Situ (2) · Colonic Neoplasms (2) · Edema (2) · Erythema (2)
Breast Diseases (48) · Neoplasms (48) · Neoplasms by Site (48) · Skin Diseases (48) · Skin and Connective Tissue Diseases (48) · Breast Neoplasms (13) · Neoplasms by Histologic Type (9) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7)
Paclitaxel (10) · Taxes (10) · pembrolizumab (9) · Carboplatin (8) · Doxorubicin (6) · Cyclophosphamide (4) · Albumin-Bound Paclitaxel (3) · Capecitabine (3) · Immunoglobulin G (3) · veliparib (3) · 130-nm albumin-bound paclitaxel (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · CTLA-4 Antigen (2) · Celecoxib (2) · Cisplatin (2)
National Cancer Institute (NCI) (16) · M.D. Anderson Cancer Center (9) · City of Hope Medical Center (4) · Northwestern University (3) · Roswell Park Cancer Institute (2) · University of Washington (2) · Vanderbilt-Ingram Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Andrei Iagaru (1) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1)
United States (46) · Canada (1) · Guam (1) · Puerto Rico (1) · South Africa (1)
Patricia LoRusso (2) · Shannon Puhalla (2) · Vandana Abramson, MD (2) · Amulya C Yellala, MD (1) · Andrei M Iagaru, MD (1) · Azadeh Nasrazadani (1) · Bhavana Pothuri (1) · Bhuvaneswari Ramaswamy, MD (1) · Bora Lim, MD (1) · Carlos H Barcenas (1) · Cristofanilli Massimo, MD (1) · Daniel Renouf (1) · Ewa Mrozek (1) · Farrokh Dehdashti (1) · Gaiane M Rauch (1)
PMID 32379297, PMID 25947565, PMID 26056183, PMID 26123926, PMID 28620884, PMID 31266460, PMID 32060053, PMID 34092112, PMID 34616010, PMID 34749008, PMID 35617923, PMID 35771552, PMID 36155347, PMID 36306810, PMID 36658425, PMID 37294342, PMID 37621406, PMID 37707811, PMID 37707822, PMID 38236702, PMID 39169033, PMID 39558017, PMID 40152443
P30CA016672 (3), P30CA060553 (3), N01CM62204 (2), P30CA006516 (2), P30CA013330 (2), P30CA016058 (2), P30CA022453 (2), P30CA047904 (2), P30CA068485 (2), U01CA062487 (2), U01CA062490 (2), U01CA099168 (2), U10CA180820 (2), UM1CA186716 (2), N01CM00070 (1)